Wordt geladen...
ERK inhibition effectively overcomes acquired resistance of EGFR-mutant NSCLC cells to osimertinib
BACKGROUND: Osimertinib (AZD9291), a third generation mutation-selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (EGFR-TKI), is an approved drug for non-small cell lung cancer (NSCLC) patients with activating EGFR mutations or those harboring resistant T790M mutation. Unfor...
Bewaard in:
| Gepubliceerd in: | Cancer |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7050394/ https://ncbi.nlm.nih.gov/pubmed/31821539 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32655 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|